Nicola J Curtin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7836235/publications.pdf

Version: 2024-02-01

157 papers	17,618 citations	22153 59 h-index	13771 129 g-index
162 all docs	162 docs citations	162 times ranked	19801 citing authors

#	Article	IF	Citations
1	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 2005, 434, 913-917.	27.8	4,382
2	Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM. Cancer Research, 2004, 64, 9152-9159.	0.9	1,089
3	DNA repair dysregulation from cancer driver to therapeutic target. Nature Reviews Cancer, 2012, 12, 801-817.	28.4	851
4	Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361. Journal of the National Cancer Institute, 2004, 96, 56-67.	6.3	459
5	Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441. Cancer Research, 2006, 66, 5354-5362.	0.9	371
6	Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 7917-7923.	7.0	361
7	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery, 2017, 7, 620-629.	9.4	321
8	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	5.0	320
9	Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. Molecular Aspects of Medicine, 2013, 34, 1217-1256.	6.4	312
10	Resistance-Modifying Agents. 9.1Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase. Journal of Medicinal Chemistry, 2000, 43, 4084-4097.	6.4	276
11	Poly(ADP-ribose) polymerase inhibition: past, present and future. Nature Reviews Drug Discovery, 2020, 19, 711-736.	46.4	275
12	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Molecular Cancer Therapeutics, 2007, 6, 945-956.	4.1	266
13	The role of PARP in DNA repair and its therapeutic exploitation. British Journal of Cancer, 2011, 105, 1114-1122.	6.4	263
14	Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Research, 2003, 63, 6008-15.	0.9	260
15	Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors. Clinical Cancer Research, 2010, 16, 2344-2351.	7.0	244
16	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Medicine, 2011, 17, 875-882.	30.7	238
17	Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2. Journal of the National Cancer Institute, 2011, 103, 334-346.	6.3	235
18	Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles. Journal of Medicinal Chemistry, 2000, 43, 2797-2804.	6.4	203

#	Article	IF	Citations
19	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology, 2002, 9, 745-749.	9.7	198
20	PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine, 2005, 7, 1-20.	3.9	190
21	Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. British Journal of Cancer, 2011, 105, 372-381.	6.4	173
22	Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells. Clinical Cancer Research, 2004, 10, 881-889.	7.0	167
23	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemotherapy and Pharmacology, 2013, 71, 1191-1199.	2.3	164
24	Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach. Journal of Medicinal Chemistry, 2005, 48, 7829-7846.	6.4	163
25	Opportunities for the repurposing of PARP inhibitors for the therapy of nonâ€oncological diseases. British Journal of Pharmacology, 2018, 175, 192-222.	5.4	160
26	Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers, 2017, 9, 41.	3.7	156
27	Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 210-213.	6.4	152
28	DNA damage checkpoint kinases in cancer. Expert Reviews in Molecular Medicine, 2020, 22, e2.	3.9	150
29	Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer. Molecular Cancer Therapeutics, 2013, 12, 959-967.	4.1	142
30	Targeting the S and G2 checkpoint to treat cancer. Drug Discovery Today, 2012, 17, 194-202.	6.4	138
31	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. British Journal of Cancer, 2016, 114, 723-730.	6.4	132
32	Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity:Â Design, Synthesis, and X-ray Cocrystal Structure. Journal of Medicinal Chemistry, 2002, 45, 4961-4974.	6.4	130
33	Resistance-Modifying Agents. 5.1Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP). Journal of Medicinal Chemistry, 1998, 41, 5247-5256.	6.4	127
34	N2-SubstitutedO6-Cyclohexylmethylguanine Derivatives:Â Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2. Journal of Medicinal Chemistry, 2004, 47, 3710-3722.	6.4	116
35	DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Research and Treatment, 2014, 143, 47-55.	2.5	116
36	Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K. Molecular Cancer Therapeutics, 2012, 11, 1789-1798.	4.1	112

#	Article	IF	Citations
37	Clinicopathological Features of Homologous Recombinationâ€“Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival. Cancer Research, 2012, 72, 5675-5682.	0.9	109
38	The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks. Clinical Cancer Research, 2005, 11, 8449-8457.	7.0	105
39	Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1. Clinical Cancer Research, 2005, 11, 3402-3409.	7.0	103
40	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research, 2010, 70, 6268-6276.	0.9	102
41	Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?. , 2020, 207, 107450.		101
42	Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene, 2004, 23, 7322-7329.	5.9	98
43	Imagestream detection and characterisation of circulating tumour cells â€“ A liquid biopsy for hepatocellular carcinoma?. Journal of Hepatology, 2016, 65, 305-313.	3.7	98
44	Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 withO6-Substituted Guanine Derivatives. Journal of Medicinal Chemistry, 2002, 45, 3381-3393.	6.4	90
45	Isoindolinone-based inhibitors of the MDM2â€“p53 proteinâ€“protein interaction. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1515-1520.	2.2	89
46	Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Molecular Cancer Therapeutics, 2009, 8, 407-414.	4.1	89
47	Visualization of a DNA-PK/PARP1 complex. Nucleic Acids Research, 2012, 40, 4168-4177.	14.5	89
48	Pyranone, Thiopyranone, and Pyridone Inhibitors of Phosphatidylinositol 3-Kinase Related Kinases. Structureâ^'Activity Relationships for DNA-Dependent Protein Kinase Inhibition, and Identification of the First Potent and Selective Inhibitor of the Ataxia Telangiectasia Mutated Kinase. Journal of Medicinal Chemistry, 2007, 50, 1958-1972.	6.4	79
49	PARP inhibitors for anticancer therapy. Biochemical Society Transactions, 2014, 42, 82-88.	3.4	78
50	The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Therapeutic Advances in Medical Oncology, 2011, 3, 257-267.	3.2	76
51	Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma. Clinical Cancer Research, 2009, 15, 1241-1249.	7.0	75
52	Untangling the ATRâ€CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Molecular Oncology, 2015, 9, 569-585.	4.6	75
53	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Molecular Cancer Therapeutics, 2015, 14, 2735-2743.	4.1	75
54	DNA-PKâ€"A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. Clinical Cancer Research, 2015, 21, 925-933.	7.0	74

#	Article	IF	Citations
55	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Molecular Cancer Therapeutics, 2005, 4, 1328-1337.	4.1	73
56	Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2433-2437.	2.2	71
57	Structure-Based design of 2-Arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-Dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3079-3082.	2.2	69
58	Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. British Journal of Cancer, 2009, 101, 256-262.	6.4	68
59	Searching for Cyclin-Dependent Kinase Inhibitors Using a New Variant of the Cope Elimination. Journal of the American Chemical Society, 2006, 128, 6012-6013.	13.7	64
60	Inhibiting the <scp>DNA</scp> damage response as a therapeutic manoeuvre in cancer. British Journal of Pharmacology, 2013, 169, 1745-1765.	5.4	64
61	Defective homologous recombination in human cancers. Cancer Treatment Reviews, 2012, 38, 89-100.	7.7	60
62	Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib. Clinical Cancer Research, 2017, 23, 2050-2060.	7.0	60
63	Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget, 2015, 6, 32396-32409.	1.8	59
64	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clinical Cancer Research, 2003, 9, 2711-8.	7.0	59
65	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British Journal of Cancer, 2010, 103, 1588-1596.	6.4	58
66	Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica, 2013, 98, 1397-1406.	3.5	58
67	Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?. Clinical Cancer Research, 2009, 15, 6106-6112.	7.0	57
68	Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochemical Journal, 2011, 436, 671-679.	3.7	56
69	Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. British Journal of Cancer, 2010, 102, 342-350.	6.4	55
70	Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemotherapy and Pharmacology, 2012, 69, 155-164.	2.3	55
71	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 217-222.	2.2	54
72	Repositioning PARP inhibitors for SARSâ€CoVâ€2 infection(COVIDâ€19); a new multiâ€pronged therapy for acute respiratory distress syndrome?. British Journal of Pharmacology, 2020, 177, 3635-3645.	5.4	52

#	Article	IF	Citations
73	Poly(ADP-Ribose) Polymerase-1 and DNA-Dependent Protein Kinase Have Equivalent Roles in Double Strand Break Repair Following Ionizing Radiation. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1520-1527.	0.8	51
74	The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice. Molecular Cancer Therapeutics, 2011, 10, 2320-2329.	4.1	50
75	Resistance-Modifying Agents. 8. Inhibition of O6-Alkylguanine-DNA Alkyltransferase by O6-Alkenyl-, O6-Cycloalkenyl-, and O6-(2-Oxoalkyl)guanines and Potentiation of Temozolomide Cytotoxicity in Vitro by O6-(1-Cyclopentenylmethyl)guanine. Journal of Medicinal Chemistry, 2000, 43, 4071-4083.	6.4	49
76	Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer. PLoS ONE, 2011, 6, e20311.	2.5	47
77	Design, Synthesis, and Evaluation of 3,4-Dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as Inhibitors of Poly(ADP-Ribose) Polymerase. Journal of Medicinal Chemistry, 2004, 47, 5467-5481.	6.4	46
78	1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity. Journal of Medicinal Chemistry, 2013, 56, 6386-6401.	6.4	45
79	Highâ€resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. International Journal of Cancer, 2016, 138, 206-216.	5.1	45
80	The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis. PLoS ONE, 2014, 9, e90604.	2.5	42
81	Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer, 2014, 110, 1977-1984.	6.4	42
82	Resistance-Modifying Agents. 11.1Pyrimido[5,4-d]pyrimidine Modulators of Antitumor Drug Activity. Synthesis and Structureâ^'Activity Relationships for Nucleoside Transport Inhibition and Binding to Î±1-Acid Glycoprotein. Journal of Medicinal Chemistry, 2004, 47, 4905-4922.	6.4	41
83	DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype. Journal of Medicinal Chemistry, 2010, 53, 8498-8507.	6.4	40
84	Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma. Current Opinion in Oncology, 2014, 26, 428-433.	2.4	36
85	Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. British Journal of Cancer, 2014, 111, 1319-1326.	6.4	36
86	Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radioâ€resistance in breast cancer. Molecular Oncology, 2016, 10, 213-223.	4.6	33
87	PARP1 expression, activity andex vivosensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. Oncotarget, 2015, 6, 43978-43991.	1.8	31
88	Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design. Breast, 2012, 21, 20-26.	2.2	30
89	Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opinion on Therapeutic Targets, 2007, 11, 783-799.	3.4	28
90	The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation. Cancers, 2018, 10, 275.	3.7	28

#	Article	IF	Citations
91	Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances, 2018, 2, 1157-1169.	5.2	28
92	Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. Oncotarget, 2017, 8, 69779-69796.	1.8	27
93	Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH). Oncotarget, 2017, 8, 104478-104491.	1.8	27
94	8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK). Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4885-4890.	2.2	26
95	Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors. Organic and Biomolecular Chemistry, 2010, 8, 2397.	2.8	26
96	Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. Oncotarget, 2018, 9, 13139-13153.	1.8	25
97	ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms. Cancers, 2020, 12, 1095.	3.7	24
98	Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. British Journal of Cancer, 2014, 111, 94-100.	6.4	23
99	Development of pharmacodynamic biomarkers for ATR inhibitors. Molecular Oncology, 2015, 9, 463-472.	4.6	22
100	Warburg and Krebs and related effects in cancer. Expert Reviews in Molecular Medicine, 2019, 21, e4.	3.9	22
101	Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Frontiers in Oncology, 2020, 10, 371.	2.8	22
102	Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 206-213.	2.5	21
103	Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody. Journal of Hepatology, 1986, 2, 25-31.	3.7	20
104	Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. Oncotarget, 2017, 8, 113418-113430.	1.8	20
105	A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Research and Treatment, 2008, 111, 55-63.	2.5	19
106	Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. Nature Reviews Clinical Oncology, 2019, 16, 725-726.	27.6	19
107	Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting. Cancers, 2020, 12, 1939.	3.7	18
108	Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells. Cancers, 2020, 12, 878.	3.7	18

#	Article	IF	Citations
109	Modulation of dipyridamole action by Î±1acid glycoprotein. Biochemical Pharmacology, 1989, 38, 3281-3288.	4.4	17
110	Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemotherapy and Pharmacology, 2010, 66, 807-812.	2.3	17
111	mTORC1 and DNAâ€PKcs as novel molecular determinants of sensitivity to Chk1 inhibition. Molecular Oncology, 2016, 10, 101-112.	4.6	17
112	Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself. PLoS ONE, 2015, 10, e0118187.	2.5	17
113	Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. Biochemical Pharmacology, 1988, 37, 2113-2120.	4.4	16
114	Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2. Organic and Biomolecular Chemistry, 2007, 5, 1577.	2.8	16
115	Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. Cell Cycle, 2008, 7, 3898-3907.	2.6	16
116	PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 429-432.	2.3	14
117	Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors. Drug Discovery Today: Disease Models, 2012, 9, e51-e58.	1.2	14
118	PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR in Biomedicine, 2017, 30, e3736.	2.8	14
119	The quantitation by radioimmunoassay of 2â€²-deoxyuridine 5â€²-triphosphate in extracts of thymidylate synthase-inhibited cells. Analytical Biochemistry, 1989, 177, 347-352.	2.4	13
120	Nucleoside Transport Inhibitors: Structureâ^'Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of Î±1-Acid Glycoprotein. Journal of Medicinal Chemistry, 2011, 54, 1847-1859.	6.4	13
121	Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. European Journal of Cancer, 2011, 47, 2052-2059.	2.8	12
122	Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types. Cancers, 2019, 11, 354.	3.7	12
123	The Development of Rucaparib/RubracaÂ®: A Story of the Synergy Between Science and Serendipity. Cancers, 2020, 12, 564.	3.7	12
124	Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors. International Journal of Gynecological Cancer, 2016, 26, 763-769.	2.5	11
125	Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4- d]pyrimidines that inhibit nucleoside transport in the presence of Î± 1 -acid glycoprotein (AGP). Bioorganic and Medicinal Chemistry Letters, 2000, 10, 585-589.	2.2	10
126	Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole22Abbreviations: ENT, equilibrative nucleoside transporter; CNT, concentrative nucleoside transporter; DP, dipyridamole; HPX, hypoxanthine; NBTI, nitrobenzylthioinosine; TdR, thymidine; Kt, kinetic constant for tansport; and Tmax, maximum velocity for transport.. Biochemical Pharmacology, 2001, 61, 477-484.	4.4	9

#	Article	IF	Citations
127	Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. Molecular Cancer Therapeutics, 2009, 8, 1828-1837.	4.1	9
128	Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity. International Journal of Gynecological Cancer, 2016, 26, 1004-1011.	2.5	9
129	Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor. Cancer Medicine, 2018, 7, 4744-4754.	2.8	9
130	Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors. Biochemical Pharmacology, 2019, 167, 125-132.	4.4	9
131	Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers, 2021, 13, 6215.	3.7	8
132	Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. Cancers, 2021, 13, 1420.	3.7	7
133	The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients. Methods in Molecular Biology, 2017, 1608, 343-370.	0.9	7
134	PARP Inhibitors and Cancer Therapy. , 2006, , 218-233.		5
135	The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy; Use as a Single Agent in Susceptible Patients; Techniques Used to Identify Susceptible Patients. Methods in Molecular Biology, 2011, 780, 239-266.	0.9	5
136	Strategies Employed for the Development of PARP Inhibitors. Methods in Molecular Biology, 2011, 780, 463-489.	0.9	5
137	PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues â€“ A population pharmacokinetic/pharmacodynamic analysis of rucaparib. Clinical Pharmacology in Drug Development, 2015, 4, 89-98.	1.6	4
138	A radioimmunoassay for deoxythymidine triphosphate. Biochemical Society Transactions, 1989, 17, 1052-1052.	3.4	3
139	Strategies Employed for the Development of PARP Inhibitors. Methods in Molecular Biology, 2017, 1608, 271-297.	0.9	3
140	Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations. Journal of Pathology: Clinical Research, 2021, , .	3.0	3
141	The Role of PARP in DNA Repair and its Therapeutic Exploitation. , 2012, , 55-73.		2
142	PARP inhibitors target ATM+p53-defective gastric cancer. Cell Cycle, 2014, 13, 3161-3162.	2.6	2
143	PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer. Cancers, 2020, 12, 3494.	3.7	2
144	Changes in developmental-specific enzyme activities during experimental hepatocarcinogenesis in the rat in vivo. Biochemical Society Transactions, 1980, 8, 94-94.	3.4	1

#	Article	IF	Citations
145	Controlled stepwise conversion of 2,4,6,8-tetrachloropyrimido[5,4-d]pyrimidine into 2,4,6,8-tetrasubstituted pyrimido[5,4-d]pyrimidines. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 108-115.	1.3	1
146	High Activity of Poly(ADP-Ribose) Polymerase in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 1788-1788.	1.4	1
147	Inhibition of DNA repair as a therapeutic target. , 2008, , 284-304.		0
148	Implications of homologous recombination defectiveness in ovarian cancer. , 0, , 75-82.		0
149	Inhibition of DNA Repair as a Therapeutic Target. , 2014, , 193-237.		0
150	PARP. , 2017, , 913-934.		0
151	Targeting ATR for Cancer Therapy: Profile and Expectations for ATR Inhibitors. Cancer Drug Discovery and Development, 2018, , 63-97.	0.4	0
152	Differences in Durability of PARP Inhibition by PARP Inhibitors in Ovarian Cancer Cells. Medical Sciences Forum, 2021, 3, .	0.5	0
153	Increased Replication Stress Sensitises High Risk Neuroblastoma Cells to ATR and PARP Inhibition. Medical Sciences Forum, 2021, 3, .	0.5	0
154	ATR as a Therapeutic Target. , 2013, , 211-228.		0
155	PARP. , 2014, , 1-22.		0
156	Biomarkers for PARP Inhibitors. Cancer Drug Discovery and Development, 2015, , 553-579.	0.4	0
157	Clinico-pathological correlation of homologous recombination status in epithelial ovarian cancer: Surgeonâ€™s perspective. , 2016, 02, .		0